These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12478233)

  • 1. Clinical experience with drug-eluting stents.
    Drachman DE
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S31-7. PubMed ID: 12478233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.
    Chong PH; Cheng JW
    Ann Pharmacother; 2004 May; 38(5):845-52. PubMed ID: 15039482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restenosis in percutaneous coronary intervention--is drug-eluting stent the answer?
    Lim VY; Lim YL
    Singapore Med J; 2003 Sep; 44(9):482-7. PubMed ID: 14740779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.
    Holmes DR; Leon MB; Moses JW; Popma JJ; Cutlip D; Fitzgerald PJ; Brown C; Fischell T; Wong SC; Midei M; Snead D; Kuntz RE
    Circulation; 2004 Feb; 109(5):634-40. PubMed ID: 14769686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future.
    Leon MB; Bakhai A;
    Am Heart J; 2003 Oct; 146(4 Suppl):S13-7. PubMed ID: 14564301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS.
    Perin EC
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents: from randomized trials to the real world.
    Saia F; Degertekin M; Lemos PA; Serruys PW
    Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
    Iijima R; Mehilli J; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
    Kavanagh CA; Rochev YA; Gallagher WM; Dawson KA; Keenan AK
    Pharmacol Ther; 2004 Apr; 102(1):1-15. PubMed ID: 15056495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents.
    Lowe HC; Schwartz RS; Mac Neill BD; Jang IK; Hayase M; Rogers C; Oesterle SN
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):515-23. PubMed ID: 14624433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.